
Editing LDL at Its Source: The Promise of VERVE-102
VERVE-102 uses base editing to switch off PCSK9 production within liver cells after one intravenous infusion. In an early trial, the highest dose lowered LDL cholesterol by 62%, approaching results achieved with today’s strongest PCSK9 treatments. However, approved injections have far more safety experience and proven cardiovascular benefits. This patient-friendly review explains the promise, practical advantages, limitations, and unanswered questions surrounding this potentially lasting treatment.
Published
Categorized as Dr. Tashko’s Key Clinical Trials, Heart Health, Insights from Dr. Tashko, Lipid Health

